placeholder

RezūmTM
Water Vapour Therapy

Durable relief for your patients

What is the data behind Water Vapour Therapy with Rezūm?

Rezūm Water Vapour Therapy is a thermal therapy, which uses convective water vapour to ablate excess prostate tissue in men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).1

It is a minimally invasive option for men who may not want to rely on pharmaceutical management of their symptoms. This advanced technology can enable you to achieve significant clinical improvements and a lasting response for your patients.1,2

How does it work?

New randomised clinical evidences

The VAPEUR randomized controlled trial (RCT) compared Rezūm™ Water Vapour Therapy to combination drug therapy in sexually active men with symptomatic BPH after alpha-blocker failure.

In the VAPEUR RCT study, Rezūm™ demonstrated significantly greater improvement in lower urinary tract symptoms (IPSS) at 1 year compared to combination medical therapy (alpha-blocker + 5-ARI), supporting its effectiveness as a next-step treatment after alpha-blocker failure.

Rezūm Water Vapour Therapy Provides symptomatic relief that is clinically meaningful and superior to standard combination medications for patients not responding to alpha-blockers.

Rezūm Water Vapour Therapy can deliver benefits in three key areas:

Long-term Durability

Rezūm uses convective energy to remove obstructive prostate tissue with a surgical retreatment rate of only 4.4% at 5 years

Surgical retreatment rate after Rezūm treatment
rezum treatment
Sustained Symptom Relief and QOL Improvement

In VAPEUR RCT study, Rezūm™’s safety profile was consistent with a minimally invasive procedure, with most procedure-related events resolving within the first year.

Combined with strong symptom outcomes and preservation of sexual function, this contributes to a favorable benefit-risk profile for appropriately selected patients.

Long-term durability has also been demonstrated in the Rezūm™ randomized pivotal study, with sustained improvements in symptoms and quality of life through 5 years.3

Rezūm™ Randomized Pivotal Study – 5-Year Outcomes (vs baseline)3:

graphics-sustained-symptom-relief-QOL-improvements

Versatile to Treat Median Lobe Obstruction (MLO)

rezum treatment study rate

 

Rezūm can treat lateral and central zones without physicians having to learn an advanced of men in study technique

Positive Safety Profile and Preserves Sexual Function

checkmark-on-shield

 

Rezūm™ has been shown to preserve sexual function through 1 year — a differentiating outcome compared with combination medical therapy, where declines in sexual function were observed.

This aligns with the overall goal of reducing LUTS without compromising sexual health outcomes — a key concern for many patients.

What is the potential value for your treatment centre?

VAPEUR data suggest Rezūm™ can be a meaningful and effective option after failure of Alpha-blocker medical therapy, possibly helping healthcare centres reduce medication burden and deliver durable symptom relief.

This supports treatment decisions earlier in the care pathway for patients seeking alternatives to chronic combination drug regimens.

 

Not only does Rezūm possess a minimal learning curve for physicians,1 it can also deliver value to your centre through its short procedural time and length of stay.1,8 In some countries cost modelling estimates that Rezūm is cost saving compared with standard treatments.12 Identification of treatments for LUTS/BPH that demonstrate cost-effectiveness is paramount** as reimbursement for patient care moves from volume-based services to value-based services.9

 

With its durable clinical benefits 1, short procedural time and short length of stay1,8 Rezūm may lead to cost savings 10,11 as well as capacity impact reduction vs standard of care*.11

Discover Rezūm Clinical Evidence

How can we help you?

EXPERTCARE SERVICE

Technical expertise

Our team is knowledgeable and available to work with you remotely and on site.

Find more info

EDUCARE

Continuous learning

Our tailored e-learning platform and in-person training can help you reach your goals

Explore the offering

COLLABORATION

Commercial contracting

Our solutions are based on partnership, innovation and value for patients and hospitals

Contact us

 

1. McVary KT, Rogers T, Roehrborn CG. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology. 2019;126:171–17

2.McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021:206(3):715–724.*

3. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water vapor thermal therapy for treatment ofmoderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021 Apr 19. Online ahead of print.

4. Rezum II Trial – BSC data on file.

5. McVary KT, Roehrborn CG. Three-Year Outcomes of the Prospective, Randomized Controlled Rezūm™ System Study: Convective Radiofrequency Thermal Therapy for Treatmentof Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Urology. Elsevier Inc.; 2018;111: 1–9. doi:10.1016/j.urology.2017.10.023.

6. McVary KT, Rogers T, Roehrborn CG. Rezūm™ Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year ResultsFrom Randomized Controlled Study. Urology. Elsevier Inc.; 2019;126: 171–179. doi:10.1016/j.urology.2018.12.041.

7. McVary KT, Roehrborn C. Five year results of the prospective, arndomized, controlled trial of water thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.J Urol. 2020;203: e1021

8. Westwood J, Geraghty R, Jones P, et al. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol. 10(11):327–333.

9. Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2017;10:29–43.

10. NICE Guidance on Rezum https://www.nice.org.uk/guidance/mtg49/chapter/1-Recommendations

11. Rob S Blissett, Deirdre B Blissett, Martina Oselin, et al. Transurethral water vapor therapy for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a cost-minimization and budget impact analysis from an Italian healthcare perspective, Minerva Urol Nephrol. 2022 Dec 23.

12. Alberto De la Cuadra-Grande, Jorge Rioja-Zuazu,Mario Domínguez-Esteban, et al., Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system, Expert Rev Pharmacoecon Outcomes Res. 2023 Mar 20;1-12.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.

The Rezūm System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. It is indicated for men with a prostate volume ≥ 30 cm3.The Rezūm System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe.

All images are the property of Boston Scientific.

All trademarks are the property of their respective owners.